Baotou Dongbao Bio-Tech Co Ltd - Asset Resilience Ratio
Baotou Dongbao Bio-Tech Co Ltd (300239) has an Asset Resilience Ratio of -1.38% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Baotou Dongbao Bio-Tech Co Ltd (300239) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how Baotou Dongbao Bio-Tech Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Baotou Dongbao Bio-Tech Co Ltd balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Baotou Dongbao Bio-Tech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 300239 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥-37.84 Million | -1.38% |
| Total Liquid Assets | CN¥-37.84 Million | -1.38% |
Asset Resilience Insights
- Limited Liquidity: Baotou Dongbao Bio-Tech Co Ltd maintains only -1.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Baotou Dongbao Bio-Tech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Baotou Dongbao Bio-Tech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Baotou Dongbao Bio-Tech Co Ltd (None–None)
The table below shows the annual Asset Resilience Ratio data for Baotou Dongbao Bio-Tech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About Baotou Dongbao Bio-Tech Co Ltd
Baotou Dongbao Bio-Tech Co.,Ltd engages in the design, research and development, production, and sale of gelatin and collagen in the People's Republic of China and internationally. It offers pharmaceutical gelation, food additives gelatin, and photographic gelatin; hydrolyzed collagen, collagen peptide, fish collagen peptide, and agglomerated collagen; and private label collagen and unflavored co… Read more